The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171

Eric A. Klein, Tomasz M. Beer, Michael Seiden

Research output: Contribution to journalComment/debatepeer-review

2 Scopus citations

Abstract

Multicancer Early Detection (MCED) represents a new and exciting paradigm for the early detection of cancer, which is the leading cause of death worldwide. Current screening tests, recommended for only five cancer types (breast, lung, colon, cervical, and prostate), are limited by a lack of complete adherence to guideline-based use and by the fact that they have cumulative high false positive rates. MCED tests agnostically detect cancer signals in the blood with good sensitivity and low false positive rates, can predict the cancer site of origin with high accuracy, can detect highly lethal cancers that have no current screening tests, and promise to improve cancer screening by improving efficiency and reducing the overall number needed to screen. Herein we outline this promise and clarify several published misconceptions about this field.

Original languageEnglish (US)
Article number1243
JournalDiagnostics
Volume12
Issue number5
DOIs
StatePublished - May 2022

Keywords

  • circulating cell-free genome atlas
  • methylation
  • multicancer early detection

ASJC Scopus subject areas

  • Clinical Biochemistry

Fingerprint

Dive into the research topics of 'The Promise of Multicancer Early Detection. Comment on Pons-Belda et al. Can Circulating Tumor DNA Support a Successful Screening Test for Early Cancer Detection? The Grail Paradigm. Diagnostics 2021, 11, 2171'. Together they form a unique fingerprint.

Cite this